Short description
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Description
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer.
Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Wilmington, Delaware, United States, North America
Founded on
January 1, 2016
Exited on
September 24, 2020
Went public on
September 24, 2020
Stock symbol
PRLD
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$1230 - 4560
Sign in for full access
Investors
Blurry Noaccess, Noaccessforu
Sign in for full access
Founders
Krishna Vaddi